Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Performance was driven by strong double-digit growth across the existing commercial product portfolio, particularly KEDRAB in the U.S. and international markets.
Management attributes record financial results to a four-pillar strategy focusing on commercial sales, distribution expansion, plasma collection, and M&A. Operational synergies and disciplined expense management allowed the company to maintain a 26% adjusted EBITDA margin despite shifting product mixes. The company is successfully transitioning to a vertically integrated model, utilizing its own Texas-based plasma collection centers to support both external supply agreements and internal production.
The Distribution segment is expanding through the launch of biosimilars in Israel and new agreements in the MENA region to diversify revenue streams. Strategic investments in post-marketing research for CYTOGAM are intended to demonstrate clinical advantages in transplant recipients and drive increased utilization. Management reiterated 2026 annual guidance of $200 million to $205 million in revenue, assuming the commencement of plasma sales in the fourth quarter.
The new 3-year, $50 million plasma supply agreement is expected to contribute approximately $17 million annually, effectively utilizing the capacity of two collection centers. Biosimilar annual sales are projected to reach between $15 million to $20 million within the next few years as more products from the pipeline are launched. Future growth acceleration is contingent on the execution of M&A transactions, which remain a core focus to complement current organic double-digit growth.
The company expects to maintain its track record of converting operating profits into cash flow to support ongoing investments and shareholder returns. CFO Chaime Orlev will depart at the end of 2026 after nine years; a search for a successor has been initiated with a transition plan in place. The company implemented a $14.4 million dividend payment during the second quarter, highlighting its strong cash position and operational health.
Approval of an in-house rabies antibody neutralizing test lab was secured to accelerate product release cycles and further vertical integration. The first-of-its-kind $50 million normal source plasma agreement validates the company's investment in U.S.-based collection infrastructure. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
